We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.
- Authors
Ferreri, Christopher J.; Hildebrandt, Michelle A. T.; Hashmi, Hamza; Shune, Leyla O.; McGuirk, Joseph P.; Sborov, Douglas W.; Wagner, Charlotte B.; Kocoglu, M. Hakan; Rapoport, Aaron; Atrash, Shebli; Voorhees, Peter M.; Khouri, Jack; Dima, Danai; Afrough, Aimaz; Kaur, Gurbakhash; Anderson Jr., Larry D.; Simmons, Gary; Davis, James A.; Kalariya, Nilesh; Peres, Lauren C.
- Abstract
Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed clinical outcomes for patients infused with standard-of-care idecabtagene vicleucel, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, at 11 US medical centers. A total of 50 patients with prior BCMA-TT exposure (38 antibody-drug conjugate, 7 bispecific, 5 CAR T) and 153 patients with no prior BCMA-TT were infused with ide-cel, with a median follow-up duration of 4.5 and 6.0 months, respectively. Safety outcomes between cohorts were comparable. The prior BCMA-TT cohort had a lower overall response rate (74% versus 88%; p = 0.021), median duration of response (7.4 versus 9.6 months; p = 0.03), and median progression-free survival (3.2 months versus 9.0 months; p = 0.0002) compared to the cohort without prior BCMA-TT. All five patients who received a prior anti-BCMA CAR T responded to ide-cel, and survival outcomes were best for this subgroup. In conclusion, treatment with ide-cel yielded meaningful clinical responses in real-world patients exposed to a prior BCMA-TT, though response rates and durability were suboptimal compared to those not treated with a prior BCMA-TT.
- Subjects
MULTIPLE myeloma; PATIENTS' attitudes; CHIMERIC antigen receptors; ANTIBODY-drug conjugates; PROGRESSION-free survival
- Publication
Blood Cancer Journal, 2023, Vol 13, Issue 1, p1
- ISSN
2044-5385
- Publication type
Article
- DOI
10.1038/s41408-023-00886-8